A Milestone in Advanced Nuclear Development
Oklo Inc., the California-based advanced nuclear energy company, has secured a significant regulatory milestone: the U.S. Department of Energy has approved a Nuclear Safety Design Agreement for the Groves Isotopes Test Reactor, a facility being developed by Oklo's wholly owned subsidiary Atomic Alchemy. The approval, made under DOE's Reactor Pilot Program, authorizes the company to advance into detailed safety design work — the technical phase that bridges concept development and construction authorization.
The agreement marks a concrete step forward in Oklo's effort to establish domestic radioisotope production capacity. Radioisotopes — radioactive versions of elements like technetium, lutetium, and actinium — are critical components of nuclear medicine, used for both imaging and therapeutic applications. They are also used in research, materials testing, and national security applications. The U.S. currently depends substantially on foreign suppliers for many medically important radioisotopes, a supply chain vulnerability that has attracted bipartisan concern in Congress.
What the NSDA Approval Means
A Nuclear Safety Design Agreement is a formal commitment between DOE and a reactor developer establishing the safety framework under which the reactor will be designed. Rather than the traditional Nuclear Regulatory Commission licensing pathway, which applies to commercial power reactors, DOE's Reactor Pilot Program provides an alternative authorization pathway specifically designed for innovative reactor concepts being developed in partnership with the department.
The NSDA approval means Oklo can now submit a Preliminary Documented Safety Analysis — a detailed technical document that describes the reactor's design, its safety systems, the hazards it poses, and the measures in place to prevent accidents. DOE will review that analysis before authorizing further development. The PDSA submission is the next formal milestone in the program.
Jacob DeWitte, Oklo's co-founder and CEO, described the approval as meaningful progress. This plant will help us gather critical data, refine our processes, and apply those lessons to subsequent licensing submissions and future deployments, he said in a statement alongside the announcement.
The Radioisotope Supply Challenge
The strategic rationale for the Groves Isotopes Test Reactor centers on a genuine and growing problem: the United States has insufficient domestic capacity to produce the full range of radioisotopes needed for nuclear medicine and research. Many critical medical isotopes are produced at a small number of aging research reactors in Canada, Europe, and elsewhere — and supply disruptions, when they occur, directly affect patient care.
Technetium-99m, used in tens of millions of diagnostic imaging procedures annually, is produced from molybdenum-99, which comes almost entirely from a handful of reactors in Belgium, the Netherlands, and South Africa. A significant outage at any of these facilities ripples through the medical system. Lutetium-177 and actinium-225, used in targeted radiotherapy for cancers including prostate cancer, are in growing demand as clinical evidence for their effectiveness accumulates. Domestic production capacity is limited, creating access challenges for patients and supply pressure on clinical trials.
Oklo's Reactor Design
Oklo is primarily known as a developer of small advanced fission reactors — compact systems using fast neutrons and liquid metal coolants that differ fundamentally from the light water reactors that dominate commercial nuclear power. The Groves Isotopes Test Reactor leverages Oklo's reactor design expertise in a specialized application focused on isotope production rather than electricity generation.
The facility is conceived as a test and demonstration platform — generating the operational data and regulatory experience that will inform future commercial-scale isotope production deployments. By operating under DOE's Reactor Pilot Program, Oklo can pursue the isotope facility on a potentially faster timeline than the NRC commercial licensing pathway allows, taking advantage of DOE's interest in demonstrating advanced reactor technologies on federal land.
The Broader Nuclear Renaissance
Oklo's progress with the Groves Isotopes Test Reactor is one thread in a broader resurgence of interest in advanced nuclear energy. Rising electricity demand from data centers and AI infrastructure, combined with the imperative to reduce carbon emissions, has led major technology companies and energy investors to bet on advanced nuclear as a scalable, carbon-free power source.
The intersection of nuclear energy and medical applications represents a different dimension of the nuclear renaissance — one focused not on electricity but on the unique isotopes that only nuclear reactors can efficiently produce at scale. Both dimensions share the common challenge of navigating a regulatory environment that was designed for a previous generation of nuclear technology and is now adapting to innovations that differ fundamentally from what the rules were written to govern.
This article is based on reporting by Interesting Engineering. Read the original article.
